发明申请
US20050245575A1 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
失效
1 - （（5-芳基-1,2,4-恶二唑-3-基）苄基）氮杂环丁烷-3-羧酸酯和1 - （（5-芳基-1,2,4-恶二唑-3-基）苄基） 吡咯烷-3-羧酸盐作为edg受体激动剂
- 专利标题： 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
- 专利标题（中）： 1 - （（5-芳基-1,2,4-恶二唑-3-基）苄基）氮杂环丁烷-3-羧酸酯和1 - （（5-芳基-1,2,4-恶二唑-3-基）苄基） 吡咯烷-3-羧酸盐作为edg受体激动剂
-
申请号： US10515192申请日： 2003-06-16
-
公开(公告)号： US20050245575A1公开(公告)日： 2005-11-03
- 发明人: Weirong Chen , Jeffrey Hale , Zhen Li , Christopher Lynch , Sander Mills , William Neway
- 申请人： Weirong Chen , Jeffrey Hale , Zhen Li , Christopher Lynch , Sander Mills , William Neway
- 国际申请： PCT/US03/18852 WO 20030616
- 主分类号： A61K31/4245
- IPC分类号： A61K31/4245 ; A61K31/454 ; A61P1/02 ; A61P1/04 ; A61P1/16 ; A61P1/18 ; A61P3/10 ; A61P7/06 ; A61P9/10 ; A61P11/00 ; A61P11/02 ; A61P11/06 ; A61P13/12 ; A61P17/00 ; A61P17/06 ; A61P17/14 ; A61P19/02 ; A61P21/00 ; A61P21/04 ; A61P25/00 ; A61P25/06 ; A61P25/28 ; A61P27/02 ; A61P27/12 ; A61P29/00 ; A61P31/00 ; A61P31/04 ; A61P31/12 ; A61P31/18 ; A61P35/00 ; A61P35/02 ; A61P37/02 ; A61P37/06 ; A61P37/08 ; A61P43/00 ; C07D413/02 ; C07D413/10 ; C07D413/14
摘要：
The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
公开/授权文献
信息查询
